These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 27746107

  • 21. A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma.
    Mei Y, Chen MM, Liang H, Ma L.
    Commun Biol; 2021 Mar 22; 4(1):383. PubMed ID: 33753855
    [Abstract] [Full Text] [Related]

  • 22. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
    Jung M, Lee J, Kim TM, Lee DH, Kang JH, Oh SY, Lee SJ, Shin SJ.
    Cancer Res Treat; 2017 Jan 22; 49(1):44-53. PubMed ID: 27121719
    [Abstract] [Full Text] [Related]

  • 23. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.
    Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Pappo A.
    Eur J Cancer; 2017 Nov 22; 86():358-363. PubMed ID: 29100190
    [Abstract] [Full Text] [Related]

  • 24. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
    Maeda T, Yanagi T, Imafuku K, Kitamura S, Hata H, Izumi K, Ujiie H, Iwata H, Shimizu H.
    Int J Dermatol; 2017 Dec 22; 56(12):1477-1479. PubMed ID: 28762466
    [No Abstract] [Full Text] [Related]

  • 25. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
    Eryılmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Başsorgun I, Coşkun HŞ.
    J Oncol Pharm Pract; 2016 Jun 22; 22(3):533-6. PubMed ID: 25694346
    [Abstract] [Full Text] [Related]

  • 26. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K, Nakamura Y, Fujisawa Y, Endo R, Tanaka R, Ishitsuka Y, Maruyama H, Watanabe R, Okiyama N, Fujimoto M.
    Eur J Dermatol; 2018 Feb 01; 28(1):129-130. PubMed ID: 29400284
    [No Abstract] [Full Text] [Related]

  • 27. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ, Carlos G, Wakade D, Sharma R, Fernandez-Penas P.
    Melanoma Res; 2016 Aug 01; 26(4):417-20. PubMed ID: 27031538
    [Abstract] [Full Text] [Related]

  • 28. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T, Hiura A, Uehara J, Toyoshima R, Nakagawa T, Yoshino K.
    Eur J Dermatol; 2021 Oct 01; 31(5):662-664. PubMed ID: 34642136
    [No Abstract] [Full Text] [Related]

  • 29. ANCA-associated vasculitic neuropathy during treatment with ipilimumab.
    Villarreal-Compagny M, Iglesias P, Marco-Hernández J, Milisenda JC, Casanova-Molla J, Hernández-Rodríguez J, Puig S, Carrera C, Prieto-González S.
    Rheumatology (Oxford); 2020 Jan 01; 59(1):251-252. PubMed ID: 31209477
    [No Abstract] [Full Text] [Related]

  • 30. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
    Page B, Borradori L, Beltraminelli H, Yawalkar N, Hunger RE.
    J Eur Acad Dermatol Venereol; 2018 Jul 01; 32(7):e256-e257. PubMed ID: 28430376
    [No Abstract] [Full Text] [Related]

  • 31. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D.
    Eur J Cancer; 2017 Sep 01; 83():142-145. PubMed ID: 28735071
    [No Abstract] [Full Text] [Related]

  • 32. Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors.
    Arangalage D, Delyon J, Lermuzeaux M, Ekpe K, Ederhy S, Pages C, Lebbé C.
    Ann Intern Med; 2017 Nov 07; 167(9):683-684. PubMed ID: 28869988
    [No Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and meta-analysis.
    Li J, Gu J.
    J Clin Pharm Ther; 2019 Jun 07; 44(3):420-429. PubMed ID: 30693536
    [Abstract] [Full Text] [Related]

  • 34. The best treatments to use after checkpoint inhibition in melanoma.
    McArthur G.
    Clin Adv Hematol Oncol; 2017 Apr 07; 15(4):242-245. PubMed ID: 28591097
    [No Abstract] [Full Text] [Related]

  • 35. Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy.
    Deutsch GB, Tyrell R, Yost S, Deutsch MB, Barkhoudarian G, Kelly DF, Faries MB.
    J Am Acad Dermatol; 2018 Feb 07; 78(2):419-421. PubMed ID: 29332716
    [No Abstract] [Full Text] [Related]

  • 36. Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
    Cervantes J, Rosen A, Dehesa L, Dickinson G, Alonso-Llamazares J.
    Actas Dermosifiliogr (Engl Ed); 2019 Feb 07; 110(1):43-49. PubMed ID: 30389125
    [Abstract] [Full Text] [Related]

  • 37. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis.
    Ludwig SV, F Cheng P, Mangana J, Braun R, Dummer R, Koelblinger P.
    Eur J Dermatol; 2020 Dec 01; 30(6):699-709. PubMed ID: 33459260
    [Abstract] [Full Text] [Related]

  • 38. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.
    Maeda T, Yoshino K, Nagai K, Oaku S, Kato M, Hiura A, Hata H.
    Eur J Cancer; 2019 Jul 01; 115():13-16. PubMed ID: 31082687
    [No Abstract] [Full Text] [Related]

  • 39. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
    Balatoni T, Ladányi A, Fröhlich G, Czirbesz K, Kovács P, Pánczél G, Bence E, Plótár V, Liszkay G.
    Pathol Oncol Res; 2020 Jan 01; 26(1):317-325. PubMed ID: 30225783
    [Abstract] [Full Text] [Related]

  • 40. Widespread biphasic amyloidosis related to ipilimumab treatment for metastatic melanoma.
    Velasco-Tamariz V, Burillo-Martínez S, Prieto-Barrios M, Calleja-Algarra A, Rodríguez-Peralto JL, Ortiz-Romero PL.
    Int J Dermatol; 2017 Sep 01; 56(9):e189-e191. PubMed ID: 28500627
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.